This drug received in September the sanitary registration from the Cuban regulatory authority to treat this disease and is now undergoing an expansive study that covers a larger number of patients throughout the country.

Dr. Raúl Cepero Morales, a specialist in Rheumatology, explained to Granma newspaper that the first part of this study took place before the Covid-19 pandemic, and now it covers the eastern region and a larger number of patients.

The specialist referred to the immunomodulatory and anti-inflammatory effects that are already taking place in the patients, who improves their quality of life, even without having finished the treatment, although he insisted that in the long term, better results will be seen.

The researcher also pointed out that no adverse effects have been registered so far in the first four doses.

In the case of its use in the treatment of rheumatoid arthritis, the State Center for the Control of Medicines and Medical Devices of the island referred in the authorization granted that the drug demonstrated quality, safety, and efficacy in the proposed indication after a rigorous process of evaluation of the evidence presented.

jrr/arm/mem/ab